Verastem Oncology to Participate in Upcoming November Investor Conferences
BOSTON–(BUSINESS WIRE)–
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to present at the following investor conferences:
- Guggenheim 3rd Annual Healthcare Innovation Conference in Boston: November 9, 4:00-4:25pm ET
- Wolfe Research Healthcare Conference in New York City: November 10, 4:00-4:30pm ET
- Jefferies London Healthcare Conference in London: November 16, 2:30-2:55pm GMT
A live webcast of the fireside chats can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261102520123/en/
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
[email protected] or
[email protected]
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Oncology General Health Health Clinical Trials
MEDIA:
| Logo |
 |